CN113924627A - 用于治疗与偏头痛相关联的症状的系统和方法 - Google Patents
用于治疗与偏头痛相关联的症状的系统和方法 Download PDFInfo
- Publication number
- CN113924627A CN113924627A CN202080023833.3A CN202080023833A CN113924627A CN 113924627 A CN113924627 A CN 113924627A CN 202080023833 A CN202080023833 A CN 202080023833A CN 113924627 A CN113924627 A CN 113924627A
- Authority
- CN
- China
- Prior art keywords
- patient
- migraine
- data
- medication
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000019695 Migraine disease Diseases 0.000 title claims abstract description 179
- 206010027599 migraine Diseases 0.000 title claims abstract description 171
- 238000000034 method Methods 0.000 title claims abstract description 47
- 208000024891 symptom Diseases 0.000 title claims abstract description 24
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 133
- 239000003814 drug Substances 0.000 claims abstract description 76
- 229940079593 drug Drugs 0.000 claims abstract description 68
- 238000012545 processing Methods 0.000 claims abstract description 36
- 238000011282 treatment Methods 0.000 claims abstract description 32
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 claims abstract description 18
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 claims abstract description 17
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 claims abstract description 17
- 239000003112 inhibitor Substances 0.000 claims abstract description 10
- 206010027603 Migraine headaches Diseases 0.000 claims abstract description 8
- 230000015654 memory Effects 0.000 claims description 45
- 238000009225 cognitive behavioral therapy Methods 0.000 claims description 22
- 238000004891 communication Methods 0.000 claims description 17
- 230000000694 effects Effects 0.000 claims description 14
- 238000010521 absorption reaction Methods 0.000 claims description 6
- 239000007943 implant Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 230000036772 blood pressure Effects 0.000 claims description 5
- 210000004243 sweat Anatomy 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 description 15
- 230000000116 mitigating effect Effects 0.000 description 11
- 230000001953 sensory effect Effects 0.000 description 10
- 238000004590 computer program Methods 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 238000010586 diagram Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 6
- 238000013473 artificial intelligence Methods 0.000 description 5
- 238000010801 machine learning Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000010340 Sleep Deprivation Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000013500 data storage Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 230000007613 environmental effect Effects 0.000 description 3
- 229960002284 frovatriptan Drugs 0.000 description 3
- SIBNYOSJIXCDRI-SECBINFHSA-N frovatriptan Chemical compound C1=C(C(N)=O)[CH]C2=C(C[C@H](NC)CC3)C3=NC2=C1 SIBNYOSJIXCDRI-SECBINFHSA-N 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- WKEMJKQOLOHJLZ-UHFFFAOYSA-N Almogran Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CS(=O)(=O)N1CCCC1 WKEMJKQOLOHJLZ-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 229960002133 almotriptan Drugs 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 229960002472 eletriptan Drugs 0.000 description 2
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229950001616 erenumab Drugs 0.000 description 2
- 229950000118 galcanezumab Drugs 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 229960005254 naratriptan Drugs 0.000 description 2
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 2
- 230000006855 networking Effects 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229960000425 rizatriptan Drugs 0.000 description 2
- TXHZXHICDBAVJW-UHFFFAOYSA-N rizatriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1CN1C=NC=N1 TXHZXHICDBAVJW-UHFFFAOYSA-N 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 229960003708 sumatriptan Drugs 0.000 description 2
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 229960001360 zolmitriptan Drugs 0.000 description 2
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/024—Detecting, measuring or recording pulse rate or heart rate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/103—Detecting, measuring or recording devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
- A61B5/11—Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb
- A61B5/1118—Determining activity level
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/70—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H80/00—ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/02—Details of sensors specially adapted for in-vivo measurements
- A61B2562/0219—Inertial sensors, e.g. accelerometers, gyroscopes, tilt switches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0002—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network
- A61B5/0004—Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network characterised by the type of physiological signal transmitted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/225—Calcitonin gene related peptide
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/13—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Primary Health Care (AREA)
- Pathology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Physiology (AREA)
- Cardiology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Psychiatry (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Signal Processing (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Developmental Disabilities (AREA)
- Social Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Computer Networks & Wireless Communication (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
Abstract
Description
Claims (20)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962809251P | 2019-02-22 | 2019-02-22 | |
US62/809,251 | 2019-02-22 | ||
PCT/US2020/019202 WO2020172520A1 (en) | 2019-02-22 | 2020-02-21 | Systems and methods for the treatment of symptoms associated with migraines |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113924627A true CN113924627A (zh) | 2022-01-11 |
Family
ID=72141449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080023833.3A Pending CN113924627A (zh) | 2019-02-22 | 2020-02-21 | 用于治疗与偏头痛相关联的症状的系统和方法 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11793472B2 (zh) |
EP (1) | EP3928328A4 (zh) |
JP (1) | JP2022521020A (zh) |
KR (1) | KR20210138590A (zh) |
CN (1) | CN113924627A (zh) |
AU (2) | AU2020225481A1 (zh) |
CA (1) | CA3130620A1 (zh) |
IL (1) | IL285627A (zh) |
NZ (1) | NZ780195A (zh) |
SG (1) | SG11202109119QA (zh) |
WO (1) | WO2020172520A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117942044A (zh) * | 2024-03-26 | 2024-04-30 | 辽宁省金秋医院 | 一种用于老年护理用镇痛评估方法及系统 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024024314A1 (ja) * | 2022-07-25 | 2024-02-01 | テルモ株式会社 | コンピュータプログラム、疼痛管理支援装置及び疼痛管理支援方法 |
WO2024024315A1 (ja) * | 2022-07-25 | 2024-02-01 | テルモ株式会社 | コンピュータプログラム、情報処理装置、情報処理方法及び学習モデル生成方法 |
WO2024024316A1 (ja) * | 2022-07-25 | 2024-02-01 | テルモ株式会社 | コンピュータプログラム、情報処理装置、情報処理方法及び学習モデル生成方法 |
WO2024024317A1 (ja) * | 2022-07-25 | 2024-02-01 | テルモ株式会社 | コンピュータプログラム、情報処理装置、情報処理方法及び学習モデル生成方法 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6284794B1 (en) * | 1996-11-05 | 2001-09-04 | Head Explorer Aps | Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase |
JP2004537526A (ja) * | 2001-06-12 | 2004-12-16 | メルク エンド カムパニー インコーポレーテッド | 片頭痛の治療又は予防用nr2b受容体拮抗薬 |
US20030144829A1 (en) * | 2002-01-25 | 2003-07-31 | Geatz Michael W. | System and method for sensing and evaluating physiological parameters and modeling an adaptable predictive analysis for symptoms management |
US7941200B2 (en) * | 2005-12-08 | 2011-05-10 | Roche Diagnostics Operations, Inc. | System and method for determining drug administration information |
JP2008237718A (ja) | 2007-03-28 | 2008-10-09 | Quality Kk | 配合出力装置および配合出力プログラム |
JP2010008825A (ja) | 2008-06-30 | 2010-01-14 | Nikon Corp | 観測光学系 |
NZ622157A (en) | 2008-12-30 | 2015-10-30 | Teva Pharmaceuticals Int Gmbh | Electronic control of drug delivery system |
EP2884888A4 (en) | 2012-08-16 | 2016-04-20 | Ginger Io Inc | METHOD FOR MODELING BEHAVIORAL AND HEALTH CHANGES |
US10665349B2 (en) | 2014-09-05 | 2020-05-26 | University Of Cincinnati | Methods for determining risk and treating diseases and conditions that correlate to weather data |
EP3226972A4 (en) | 2014-12-01 | 2018-08-08 | Achelios Therapeutics, Inc. | Methods and compositions for treating migraine and conditions associated with pain |
US11980484B2 (en) | 2015-08-26 | 2024-05-14 | Resmed Sensor Technologies Limited | Systems and methods for monitoring and management of chronic disease |
US10473955B2 (en) | 2015-11-13 | 2019-11-12 | SensorRx, Inc. | Automated digital migraine diary |
ES2634874B2 (es) | 2016-02-29 | 2018-03-16 | Fundación Para La Investigación Biomédica Del Hospital Universitario La Princesa | Método para determinar el nivel de activación del sistema trigémino-vascular |
WO2018037080A1 (en) | 2016-08-25 | 2018-03-01 | Novo Nordisk A/S | Starter kit for basal insulin titration |
JP6533243B2 (ja) * | 2017-03-01 | 2019-06-19 | ヤフー株式会社 | 提供装置、提供方法、及び提供プログラム |
-
2020
- 2020-02-21 EP EP20758656.1A patent/EP3928328A4/en active Pending
- 2020-02-21 KR KR1020217028471A patent/KR20210138590A/ko active IP Right Grant
- 2020-02-21 CN CN202080023833.3A patent/CN113924627A/zh active Pending
- 2020-02-21 NZ NZ780195A patent/NZ780195A/en unknown
- 2020-02-21 SG SG11202109119QA patent/SG11202109119QA/en unknown
- 2020-02-21 JP JP2021549518A patent/JP2022521020A/ja active Pending
- 2020-02-21 WO PCT/US2020/019202 patent/WO2020172520A1/en unknown
- 2020-02-21 US US16/797,385 patent/US11793472B2/en active Active
- 2020-02-21 AU AU2020225481A patent/AU2020225481A1/en not_active Abandoned
- 2020-02-21 CA CA3130620A patent/CA3130620A1/en active Pending
-
2021
- 2021-08-15 IL IL285627A patent/IL285627A/en unknown
-
2023
- 2023-09-11 AU AU2023229478A patent/AU2023229478A1/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117942044A (zh) * | 2024-03-26 | 2024-04-30 | 辽宁省金秋医院 | 一种用于老年护理用镇痛评估方法及系统 |
CN117942044B (zh) * | 2024-03-26 | 2024-05-28 | 辽宁省金秋医院 | 一种用于老年护理用镇痛评估方法及系统 |
Also Published As
Publication number | Publication date |
---|---|
JP2022521020A (ja) | 2022-04-04 |
KR20210138590A (ko) | 2021-11-19 |
SG11202109119QA (en) | 2021-09-29 |
US20200268324A1 (en) | 2020-08-27 |
EP3928328A4 (en) | 2022-11-02 |
IL285627A (en) | 2021-09-30 |
AU2020225481A1 (en) | 2021-10-14 |
CA3130620A1 (en) | 2020-08-27 |
NZ780195A (en) | 2024-03-22 |
WO2020172520A1 (en) | 2020-08-27 |
US11793472B2 (en) | 2023-10-24 |
EP3928328A1 (en) | 2021-12-29 |
AU2023229478A1 (en) | 2023-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11793472B2 (en) | Systems and methods for the treatment of symptoms associated with migraines | |
US11658946B2 (en) | Systems and methods for ensuring data security in the treatment of diseases and disorders using digital therapeutics | |
US20200187777A1 (en) | Digital Therapeutic Component to Optimize Induction of Buprenorphine-Containing Products | |
KR102331859B1 (ko) | 개입 및 태스킹 결정을 사용하여 치료하는 시스템들 및 방법들 | |
Ferguson | What role do systemic corticosteroids, immunotherapy, and antifungal drugs play in the therapy of allergic fungal rhinosinusitis? | |
JP2020023573A (ja) | 症状の追跡による慢性状態の治療を管理するシステムおよび方法 | |
US20130110551A1 (en) | Systems and methods for managing chronic conditions | |
Vo et al. | Home-based delivery of XR-NTX in youth with opioid addiction | |
JP7432070B2 (ja) | クラウドソーシングデータの臨床的キュレーションのためのシステム及び方法 | |
US20200372990A1 (en) | Systems and Methods for Visualizing and Modifying Treatment of a Patient Utilizing a Digital Therapeutic | |
US20220005581A1 (en) | Systems, Methods, and Devices for Generating and Administering Digital Therapeutic Placebos and Shams | |
Finan et al. | Effect of algorithm aggressiveness on the performance of the Hypoglycemia-Hyperglycemia Minimizer (HHM) system | |
US20230317270A1 (en) | Platforms for dynamically selecting messages in real-time to users via decision support tools | |
US20170132379A1 (en) | System and Method for Improving the Rate of Prescription, Accessibility, and Functionality of Asthma Action Plans | |
Haider et al. | Bilateral ocular pain and hyperemia in a patient with Paget disease of the bone | |
US20200155789A1 (en) | System and method for determining the efficacy of music therapy | |
Hamilton Jr | Listening to Evelyn |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Massachusetts Applicant after: Pyle therapeutics USA, Inc. Address before: Massachusetts Applicant before: Peyer therapy Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240218 Address after: Seoul, South Kerean Applicant after: Wilt Corp. Country or region after: Republic of Korea Address before: Massachusetts USA Applicant before: Pyle therapeutics USA, Inc. Country or region before: U.S.A. |